ClinicalTrials.gg
RecruitingNCT07483476CIRCALLUpdated Aug 26, 2026

Study of Cell-free DNA in Children and Adolescents With Acute Lymphoblastic Leukemia

An observational study in Acute Lymphoblastic Leukemia ALL, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged Up to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
205
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris — 8 open to participants now, 10 under way, 3 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Assistance Publique - Hôpitaux de Paris.

Started
2026
the only one that year
Observational
6 of 18
4 open now
Registered
18th of 18
by date

Among the 18 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2026, is one of 6 observational ones, and was the 18th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

8 of the 18 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: Up to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Minimal residual disease (MRD) monitoring is a key prognostic factor in pediatric acute lymphoblastic leukemia (ALL). Currently, MRD assessment relies mainly on cellular DNA obtained from bone marrow aspirates. Although highly informative, this approach has limitations, including the need for invasive procedures and the fact that it reflects only the bone marrow compartment.

Tumor cells release fragments of genomic DNA into the bloodstream, known as circulating cell-free DNA (cfDNA). In solid tumors, cfDNA analysis has emerged as a valuable non-invasive biomarker for disease monitoring and treatment response. Recent studies have shown that cfDNA is detectable in pediatric ALL.

This study aims to investigate whether plasma cfDNA analysis could represent an alternative or complementary approach to bone marrow-based MRD assessment. cfDNA may better reflect the global tumor burden across the entire body and allow more frequent longitudinal monitoring during treatment.

The primary objective is to assess the correlation between MRD measured in plasma cfDNA and MRD measured in bone marrow cellular DNA at two key timepoints of treatment: the end of induction (Day 29) and the end of consolidation (Day 71-78).

Secondary objectives include evaluating the correlation between peripheral blood cellular DNA and bone marrow MRD, describing clonal evolution using cfDNA throughout treatment and follow-up, exploring the concordance of genomic alterations detected in cfDNA and other biological compartments, assessing the prognostic value of cfDNA MRD for relapse risk and event-free survival, and characterizing cfDNA fragmentome and methylome signatures in patients compared with healthy controls.

The study will include children and adolescents with newly diagnosed ALL treated at two AP-HP pediatric hematology centers, as well as a control cohort of healthy children undergoing HLA typing for sibling stem cell transplant.

03

Conditions studied

  • Acute Lymphoblastic Leukemia ALL

Keywords

  • Pediatric acute lymphoblastic leukemia
  • Minimal residual disease
  • Cell-free DNA
  • Liquid biopsy
  • Fragmentomics
  • Methylome
  • Clonal evolution
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Study population Children and adolescents with newly diagnosed acute lymphoblastic leukemia treated in participating pediatric hematology centers, as well as healthy pediatric siblings undergoing HLA typing.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

ALL population

  • Age \< 18 years
  • Newly diagnosed B-cell or T-cell acute lymphoblastic leukemia
  • Absence of BCR::ABL1 rearrangement
  • For infants (\<12 months), absence of KMT2A rearrangement
  • Inclusion before initiation of therapy or chemotherapy
  • Written from legal guardians
  • Affiliation to a national health insurance system Control population
  • Age \< 18 years
  • Undergoing blood sampling for HLA typing in the context of bone marrow donor evaluation
  • Sibling of a patient with leukemia
  • Written informed consent from legal guardians
  • Affiliation to a national health insurance system

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding patients
  • Patients not affiliated with a health insurance system
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
205 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • ALL patients

    Children and adolescents (\<18 years) with newly diagnosed B-cell or T-cell acute lymphoblastic leukemia without BCR::ABL1 rearrangement (and without KMT2A rearrangement in infants), included before initiation of steroid therapy or chemotherapy.

    Other: Biological sample collection

  • Healthy control participants

    Children and adolescents (\<18 years) undergoing blood sampling for HLA typing for a sibling with leukemia.

    Other: Biological sample collection

Interventions

  • OtherBiological sample collection

    Additional peripheral blood samples will be collected during treatment and follow-up for cell-free DNA analysis. Residual samples from bone marrow and cerebrospinal fluid collected as part of standard clinical care will also be analyzed.

06

What researchers measure

Primary outcomes

  1. Correlation between plasma cfDNA MRD and bone marrow MRD

    Pearson correlation coefficient between minimal residual disease (MRD) measured in plasma circulating cell-free DNA and MRD measured in bone marrow cellular DNA. Analyses will be performed according to the type of molecular target used for MRD detection (IG/TCR rearrangements, genomic breakpoints, or pathogenic variants). End of induction (Day 29) and end of consolidation (Day 71-78)

    Time frame: Up to day 78 (end of consolidation)

Secondary outcomes

  1. Correlation between peripheral blood cellular DNA MRD and bone marrow MRD

    Pearson correlation coefficient between MRD measured in peripheral blood cellular DNA and MRD measured in bone marrow cellular DNA.

    Time frame: At day 29

  2. Correlation between peripheral blood cellular DNA MRD and bone marrow MRD

    Pearson correlation coefficient between MRD measured in peripheral blood cellular DNA and MRD measured in bone marrow cellular DNA. At day 71 to 78

    Time frame: At day 78

  3. Clonal evolution detected in cell-free DNA

    Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up

    Time frame: At day 1

  4. Clonal evolution detected in cell-free DNA

    Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up

    Time frame: At day 4

  5. Clonal evolution detected in cell-free DNA

    Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up

    Time frame: At day 8

  6. Clonal evolution detected in cell-free DNA

    Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up

    Time frame: At day 15

  7. Clonal evolution detected in cell-free DNA

    Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up

    Time frame: At day 29

  8. Clonal evolution detected in cell-free DNA

    Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up At day 71 to 78

    Time frame: At day 78

  9. Clonal evolution detected in cell-free DNA

    Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up

    Time frame: At end of maintenance

  10. Clonal evolution detected in cell-free DNA

    Mutation profiles of cfDNA across multiple timepoints during treatment and follow-up

    Time frame: 3 years after remission

  11. Concordance of genomic alterations between cfDNA and other biological compartments

    Qualitative and quantitative comparison of genomic alterations detected at diagnosis in cfDNA and in other sample types (bone marrow, cerebrospinal fluid, and other tissues if available)

    Time frame: At diagnosis

  12. Prognostic value of cfDNA MRD

    Association between cfDNA MRD levels and relapse-free survival and event-free survival

    Time frame: Up to 5 years of follow-up

  13. Fragmentome and methylome profiles of circulating DNA

    Characterization and comparison of cfDNA fragment size patterns and methylation signatures between patients and healthy controls at diagnosis and during treatment. At baseline and during treatment

    Time frame: Up to 5 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2029, 39 months after the start.

Of 145 non-industry observational studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 143. This study's planned 39 months is below that.

Counting every sponsor, half of 163 studies reached it within 49 months; a quarter within 22 and three quarters within 142.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 19, 2026
StartActual
Apr 24, 2026
Primary completionEst.
Jul 24, 2029
CompletionEst.
Apr 24, 2034
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07483476
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Apr 24, 2026
Primary completion
Jul 24, 2029 (estimated)
Completion
Apr 24, 2034 (estimated)
Last update
Aug 26, 2026

Study contacts

Marion Strullu, MD PhD
Contact
marion.strullu@aphp.fr
+330140035388 ext. +33
Jérôme Lambert, MD PhD
Contact
jerome.lambert@u-paris.fr
+330142499742 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion